Evidence map›Paper›PMID 39095808›Full record

Trial reportCardiovascular diabetology2024

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.

Pishoy Gouda, Yuxi Liu, Javed Butler, Stefano Del Prato, Nasrien E Ibrahim, Carolyn S P Lam, Thomas Marwick, Julio Rosenstock, Wilson Tang, Faiez Zannad and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04083339 (Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04083339 phase3active not recruitingnot on this map

Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

TypeinterventionalSponsorApplied Therapeutics, Inc.Ran2019 to 2025Enrolled675ConditionsDiabetic CardiomyopathiesArmsAT-001, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pishoy GoudaUniversity of Alberta, Edmonton, AB, Canada.
Yuxi LiuMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX, USA.
Stefano Del PratoInterdisciplinary Research Center "Health Science" , Sant'Anna School of Advanced Studies, Pisa, Italy.
Nasrien E IbrahimBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carolyn S P LamNational Heart Centre Singapore, Singapore, Singapore.
Thomas MarwickBaker Heart and Diabetes Institute, Melbourne, Australia.
Julio RosenstockDallas Diabetes Research Center, Dallas, TX, USA.
Wilson TangHeart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
Faiez ZannadInserm CIC and CHRU, Université de Lorraine, Nancy, France.
James JanuzziMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Justin EzekowitzUniversity of Alberta, Edmonton, AB, Canada. Jae2@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPersons with diabetes are at risk for developing a cardiomyopathy through several pathophysiological mechanisms independent of traditional risk factors for heart failure. Among those with diabetic cardiomyopathy (DbCM), the relationship between natriuretic peptides, cardiac structural abnormalities and functional capacity is largely unknown.

methodsIn this prespecified subgroup analysis of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) trial, 685 participants with asymptomatic DbCM underwent baseline echocardiography data, laboratory investigations, and functional assessments. Participants were stratified by N-terminal pro-B type natriuretic peptide (NT-proBNP) quartiles, and correlation with echocardiographic and functional parameters were assessed using Spearman correlation test.

resultsThe median NT-proBNP was 71 (Q1, Q3: 33, 135) ng/L. No association was observed between NT-proBNP concentrations and echocardiographic parameters of either diastolic or systolic dysfunction including global longitudinal strain, left ventricular ejection fraction, left ventricular mass index, left atrial volume index, E/E', or right ventricular systolic pressure. In contrast, NT-proBNP was significantly correlated with overall Kansas City Cardiomyopathy Questionnaire score (rho = - 0.10; p = 0.007), the Physical Activity Scale in the Elderly (rho = - 0.12; p = 0.004), duration of cardiopulmonary exercise testing (rho = - 0.28; p < 0.001), peak VO

conclusionAmong patients with subclinical DbCM, elevated NT-proBNP concentrations are associated with worse health status, lower activity levels, and reduced functional capacity, but not with cardiac structural abnormalities. These findings suggest that regardless of cardiac structural abnormalities, biomarker concentrations reflect important deterioration in functional capacity in affected individuals.

trial registrationARISE-HF, NCT04083339 Date Registered August 23, 2019.

Indexed as

Asymptomatic DiseasesExercise ToleranceNatriuretic Peptide, BrainPeptide FragmentsVentricular Function, LeftAgedBiomarkersDiabetic CardiomyopathiesDouble-Blind MethodFemaleFunctional StatusHumansMaleMiddle AgedPredictive Value of TestsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID39095808
PMCPMC11297788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.